A Way out or a New Prospect: the Future Development of Autologons Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Therapy

GU Wei-qiong,NING Guang
DOI: https://doi.org/10.3760/cma.j.issn.1000-6699.2012.06.001
2012-01-01
Abstract:The direetion of "radical" treatment ( complete remission ) for type 1A diabetes is to correct immune disorder and to full repair damaged pancreatic islet cells.It includes the application of immune modulators and islet β-cell replacement therapy.Autologous hematopoietic stem cell transplantation (AHSCT) is a new promising approach for the treatment of type 1A diabetes by reconstitution of immunotolerance and promoting β-cell regeneration.The candidates for AHSCT are limited to the people with early-onset diabetes and keeping obvious residual islet β-cell function.Because of the potential mechanisms underlying the action of AHSCT is still not very clear,careful balancing of the pros and coins of A HSCT is still needed by further trials and intensive studies.
What problem does this paper attempt to address?